| Trial ID: | L3725 |
| Source ID: | NCT00916604
|
| Associated Drug: |
Azd1656
|
| Title: |
To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients
|
| Acronym: |
JMAD
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: AZD1656|DRUG: Placebo
|
| Outcome Measures: |
Primary: Safety by assessment of adverse events, BP, pulse rate, plasma glucose, safety laboratory variables and ECG, Blood samples taken repeatedly during 24 hours on study day sessions | Secondary: Pharmacokinetic variables (AUC, Cmax, tmax, t½, CL/F, Ae and CLR)., Blood samples taken repeatedly during 24 hours on study day sessions|Pharmacodynamic variables (P-Glucose, S-Insulin and S-C-peptide)., Blood samples taken repeatedly during 24 hours on study day sessions
|
| Sponsor/Collaborators: |
Sponsor: AstraZeneca
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
24
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT
|
| Start Date: |
2009-05
|
| Completion Date: |
2009-10
|
| Results First Posted: |
|
| Last Update Posted: |
2009-11-03
|
| Locations: |
Research Site, Fukuoka, Japan|Research Site, Tokyo, Japan
|
| URL: |
https://clinicaltrials.gov/show/NCT00916604
|
